Replacing the thymus gland during heart surgery in infants
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests whether transplanting a child's own thymus tissue during their first heart surgery helps protect their immune system. The thymus is a small gland important for immune health, and this pilot study could lead to better recovery and fewer infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 months and 2 years old at the time of heart surgery
- Your child is scheduled for their first heart surgery through the breastbone (sternotomy)
- Your child has not had any previous heart surgery through the breastbone
- Your child has no known severe immune system problems
- Your child does not have a missing or very small thymus gland
- Your child does not have other severe birth defects unrelated to the heart
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving vitamin C to children under 2 during corrective heart surgery helps them recover better and have shorter hospital stays. If your child is eligible, they would receive vitamin C as part of their care.
This study helps mothers of babies born with heart defects learn to breastfeed directly, even when the baby needs heart surgery in the first month of life. Researchers want to see if direct breastfeeding improves health outcomes for both mother and baby during this critical time.
This study looks at how removing the thymus gland during infant heart surgery affects the immune system. It compares babies who have their thymus removed with those who have heart surgery without removing it, and with babies having other types of surgery.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This study is testing a new way to help the body accept a kidney transplant without needing lifelong anti-rejection drugs. It involves transplanting a small piece of the donor's thymus (a gland that helps the immune system) along with the kidney, to train the body to see the new kidney as part of itself.
Hear when a new Congenital Heart Disease (CHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.